Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib plus pembrolizumab versus pembrolizumab plus pemetrexed and platinum for untreated KRAS G12C-mutated advanced non-squamous NSCLC
NL-OMON60912Phase 3Suspended
- Sponsor
- Roche
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of divarasib, pembrolizumab, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoints: Progression-free survival and Overall survival. Started Dec 2025; status: suspended.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60912.